AI Article Synopsis

  • Engraftment syndrome (ES) is a common complication that occurs during recovery following both autologous and allogeneic hematopoietic stem cell transplantation (HCT), particularly after nonmyeloablative procedures.
  • In a study, 10% of patients receiving cyclophosphamide/fludarabine-based nonmyeloablative HCT experienced ES, with symptoms including fever, cough, and pulmonary issues appearing around 10 days post-transplant.
  • ES was linked to older age, female sex, and treatment with amphotericin, leading to a higher risk of transplant-related mortality and shorter survival rates, although IV methylprednisolone effectively treated the symptoms.

Article Abstract

Engraftment syndrome (ES) encompasses a constellation of symptoms that occur during neutrophil recovery after both autologous and allogeneic hematopoietic stem cell transplantation (HCT). Although it is well characterized after conventional myeloablative procedures, limited data exist on this complication after nonmyeloablative allogeneic HCT. The clinical manifestations, incidence, and risk factors associated with ES were investigated in a consecutive series of patients undergoing cyclophosphamide/fludarabine-based nonmyeloablative allogeneic HCT from a related HLA-compatible donor. Fifteen (10%) of 149 patients (median age, 53 years; range, 27-66 years) developed ES; the onset of symptoms occurred at a median of 10 days (range, 3-14 days), and they consisted of fever (100%), cough (53%), diffuse pulmonary infiltrates (100%), rash (13%), and room air hypoxia (87%). ES was more likely to develop in patients who received empiric amphotericin formulations after transplant conditioning (Fisher exact test; P=.007). In a multivariate analysis, older patient age, female sex, and treatment with amphotericin were predictors for the development of ES. Intravenous methylprednisolone led to the rapid resolution of ES; however, transplant-related mortality was significantly higher (cumulative incidence, 49% versus 16%; P=.0005), and median survival was significantly shorter (168 versus 418 days; P=.005) in patients with ES compared with non-ES patients. In conclusion, ES occurs commonly after cyclophosphamide/fludarabine-based nonmyeloablative transplantation and responds rapidly to corticosteroid treatment, but it is associated with a higher risk of nonrelapse mortality and with shorter overall survival.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2005.04.009DOI Listing

Publication Analysis

Top Keywords

nonmyeloablative allogeneic
12
engraftment syndrome
8
allogeneic hematopoietic
8
hematopoietic stem
8
stem cell
8
cell transplantation
8
allogeneic hct
8
cyclophosphamide/fludarabine-based nonmyeloablative
8
patients
5
nonmyeloablative
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!